UNIQURE NV (QURE) Fundamental Analysis & Valuation

NASDAQ:QURE • NL0010696654

Current stock price

14.73 USD
-0.89 (-5.7%)
At close:
14.73 USD
0 (0%)
After Hours:

This QURE fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

2

1. QURE Profitability Analysis

1.1 Basic Checks

  • QURE had negative earnings in the past year.
  • In the past year QURE has reported a negative cash flow from operations.
  • QURE had negative earnings in 4 of the past 5 years.
  • In the past 5 years QURE reported 4 times negative operating cash flow.
QURE Yearly Net Income VS EBIT VS OCF VS FCFQURE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 200M -200M

1.2 Ratios

  • Looking at the Return On Assets, with a value of -24.12%, QURE is in the better half of the industry, outperforming 71.62% of the companies in the same industry.
  • Looking at the Return On Equity, with a value of -100.04%, QURE is in line with its industry, outperforming 45.56% of the companies in the same industry.
Industry RankSector Rank
ROA -24.12%
ROE -100.04%
ROIC N/A
ROA(3y)-34.75%
ROA(5y)-16.3%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
QURE Yearly ROA, ROE, ROICQURE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 1K 2K 3K

1.3 Margins

  • QURE's Gross Margin of 89.53% is amongst the best of the industry. QURE outperforms 91.31% of its industry peers.
  • QURE's Gross Margin has declined in the last couple of years.
  • The Profit Margin and Operating Margin are not available for QURE so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 89.53%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-2.57%
GM growth 5YN/A
QURE Yearly Profit, Operating, Gross MarginsQURE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -500 -1K -1.5K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

4

2. QURE Health Analysis

2.1 Basic Checks

  • QURE does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • The number of shares outstanding for QURE has been increased compared to 1 year ago.
  • Compared to 5 years ago, QURE has more shares outstanding
  • QURE has a better debt/assets ratio than last year.
QURE Yearly Shares OutstandingQURE Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20M 40M 60M
QURE Yearly Total Debt VS Total AssetsQURE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M 800M

2.2 Solvency

  • Based on the Altman-Z score of -1.18, we must say that QURE is in the distress zone and has some risk of bankruptcy.
  • QURE has a Altman-Z score (-1.18) which is comparable to the rest of the industry.
  • A Debt/Equity ratio of 2.63 is on the high side and indicates that QURE has dependencies on debt financing.
  • Looking at the Debt to Equity ratio, with a value of 2.63, QURE is doing worse than 79.92% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 2.63
Debt/FCF N/A
Altman-Z -1.18
ROIC/WACCN/A
WACC6.19%
QURE Yearly LT Debt VS Equity VS FCFQURE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 200M 400M

2.3 Liquidity

  • QURE has a Current Ratio of 10.43. This indicates that QURE is financially healthy and has no problem in meeting its short term obligations.
  • Looking at the Current ratio, with a value of 10.43, QURE belongs to the top of the industry, outperforming 81.85% of the companies in the same industry.
  • A Quick Ratio of 10.43 indicates that QURE has no problem at all paying its short term obligations.
  • QURE's Quick ratio of 10.43 is amongst the best of the industry. QURE outperforms 81.85% of its industry peers.
Industry RankSector Rank
Current Ratio 10.43
Quick Ratio 10.43
QURE Yearly Current Assets VS Current LiabilitesQURE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

4

3. QURE Growth Analysis

3.1 Past

  • QURE shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 28.69%, which is quite impressive.
  • Looking at the last year, QURE shows a very negative growth in Revenue. The Revenue has decreased by -40.64% in the last year.
  • The Revenue for QURE have been decreasing by -15.56% on average. This is quite bad
EPS 1Y (TTM)28.69%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%57.89%
Revenue 1Y (TTM)-40.64%
Revenue growth 3Y-46.73%
Revenue growth 5Y-15.56%
Sales Q2Q%6.65%

3.2 Future

  • QURE is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 29.94% yearly.
  • QURE is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 122.75% yearly.
EPS Next Y2.09%
EPS Next 2Y17.58%
EPS Next 3Y29.9%
EPS Next 5Y29.94%
Revenue Next Year132.5%
Revenue Next 2Y239.24%
Revenue Next 3Y182.61%
Revenue Next 5Y122.75%

3.3 Evolution

  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
QURE Yearly Revenue VS EstimatesQURE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 200M 400M 600M 800M 1B
QURE Yearly EPS VS EstimatesQURE Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 0 5 -5

More info and screens

Find the best growth stocksShow best growing peers

1

4. QURE Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for QURE. In the last year negative earnings were reported.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for QURE. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
QURE Price Earnings VS Forward Price EarningsQURE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
QURE Per share dataQURE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2

4.3 Compensation for Growth

  • QURE's earnings are expected to grow with 29.90% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y17.58%
EPS Next 3Y29.9%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. QURE Dividend Analysis

5.1 Amount

  • No dividends for QURE!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

QURE Fundamentals: All Metrics, Ratios and Statistics

UNIQURE NV

NASDAQ:QURE (3/18/2026, 8:00:01 PM)

After market: 14.73 0 (0%)

14.73

-0.89 (-5.7%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)03-02
Earnings (Next)N/A
Inst Owners99.92%
Inst Owner Change8.02%
Ins Owners1.44%
Ins Owner Change1.12%
Market Cap917.53M
Revenue(TTM)16.10M
Net Income(TTM)-198.97M
Analysts80.91
Price Target51.51 (249.69%)
Short Float %21.69%
Short Ratio3.49
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-8.35%
Min EPS beat(2)-50.39%
Max EPS beat(2)33.69%
EPS beat(4)3
Avg EPS beat(4)6.92%
Min EPS beat(4)-50.39%
Max EPS beat(4)33.69%
EPS beat(8)5
Avg EPS beat(8)-11.92%
EPS beat(12)5
Avg EPS beat(12)-37.76%
EPS beat(16)8
Avg EPS beat(16)-19.46%
Revenue beat(2)1
Avg Revenue beat(2)-12.95%
Min Revenue beat(2)-30.8%
Max Revenue beat(2)4.9%
Revenue beat(4)1
Avg Revenue beat(4)-27.84%
Min Revenue beat(4)-75.51%
Max Revenue beat(4)4.9%
Revenue beat(8)3
Avg Revenue beat(8)-19.73%
Revenue beat(12)4
Avg Revenue beat(12)-34.69%
Revenue beat(16)5
Avg Revenue beat(16)-19.09%
PT rev (1m)0%
PT rev (3m)-9.67%
EPS NQ rev (1m)5.63%
EPS NQ rev (3m)5.34%
EPS NY rev (1m)-0.28%
EPS NY rev (3m)-5.93%
Revenue NQ rev (1m)-11.23%
Revenue NQ rev (3m)-11.23%
Revenue NY rev (1m)-4.72%
Revenue NY rev (3m)-19.14%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 57
P/FCF N/A
P/OCF N/A
P/B 4.61
P/tB 9.11
EV/EBITDA N/A
EPS(TTM)-3.53
EYN/A
EPS(NY)-3.46
Fwd EYN/A
FCF(TTM)-2.86
FCFYN/A
OCF(TTM)-2.86
OCFYN/A
SpS0.26
BVpS3.19
TBVpS1.62
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -24.12%
ROE -100.04%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 89.53%
FCFM N/A
ROA(3y)-34.75%
ROA(5y)-16.3%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-2.57%
GM growth 5YN/A
F-Score5
Asset Turnover0.02
Health
Industry RankSector Rank
Debt/Equity 2.63
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 2.97%
Cap/Sales 2.73%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 10.43
Quick Ratio 10.43
Altman-Z -1.18
F-Score5
WACC6.19%
ROIC/WACCN/A
Cap/Depr(3y)29.91%
Cap/Depr(5y)107.27%
Cap/Sales(3y)20.1%
Cap/Sales(5y)16.05%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)28.69%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%57.89%
EPS Next Y2.09%
EPS Next 2Y17.58%
EPS Next 3Y29.9%
EPS Next 5Y29.94%
Revenue 1Y (TTM)-40.64%
Revenue growth 3Y-46.73%
Revenue growth 5Y-15.56%
Sales Q2Q%6.65%
Revenue Next Year132.5%
Revenue Next 2Y239.24%
Revenue Next 3Y182.61%
Revenue Next 5Y122.75%
EBIT growth 1Y-4.29%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year20.18%
EBIT Next 3Y9.43%
EBIT Next 5Y37.02%
FCF growth 1Y4.13%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y2.61%
OCF growth 3YN/A
OCF growth 5YN/A

UNIQURE NV / QURE Fundamental Analysis FAQ

Can you provide the ChartMill fundamental rating for UNIQURE NV?

ChartMill assigns a fundamental rating of 3 / 10 to QURE.


What is the valuation status for QURE stock?

ChartMill assigns a valuation rating of 1 / 10 to UNIQURE NV (QURE). This can be considered as Overvalued.


What is the profitability of QURE stock?

UNIQURE NV (QURE) has a profitability rating of 2 / 10.


How financially healthy is UNIQURE NV?

The financial health rating of UNIQURE NV (QURE) is 4 / 10.


What is the expected EPS growth for UNIQURE NV (QURE) stock?

The Earnings per Share (EPS) of UNIQURE NV (QURE) is expected to grow by 2.09% in the next year.